WALTHAM, Mass., Sept. 4, 2008 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), (XSSE:OXGN) today announced that ZYBRESTAT(tm) (fosbretabulin), the company’s lead therapeutic product candidate, has been selected by Windhover Information and an independent expert advisory group, Campbell Alliance, as one of the top 10 most interesting oncology projects available for partnering.
